MICROBOT MEDICAL INC. Proceeds from Issuance or Sale of Equity
MICROBOT MEDICAL INC. (MBOT) reported Proceeds from Issuance or Sale of Equity of $16.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-08-11
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for the quarter ending 2025-06-30 was $4.75M, a 129.12% increase year-over-year.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for the quarter ending 2025-03-31 was $27.81M, a 1060.03% increase year-over-year.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for the quarter ending 2024-12-31 was $2.83M.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for the quarter ending 2024-09-30 was $633.00K.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for fiscal 2025 was $86.24M, a 986.68% increase from fiscal 2024.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for fiscal 2024 was $7.94M, a 21.01% increase from fiscal 2023.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for fiscal 2023 was $6.56M, a 51.67% increase from fiscal 2022.
- MICROBOT MEDICAL INC. proceeds from issuance or sale of equity for fiscal 2022 was $4.32M.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $86.24M 10-K · filed 2026-03-26 | |||
| 2025-06-30 | $4.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $32.56M 10-Q · filed 2026-08-11 | $35.39M derived: sum of 3 quarters · filed 2026-08-11 | $36.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $27.81M 10-Q · filed 2026-05-13 | $30.64M derived: sum of 2 quarters · filed 2026-05-13 | $31.27M derived: sum of 3 quarters · filed 2026-05-13 | $33.34M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $3.46M derived: sum of 2 quarters · filed 2026-03-26 | $5.54M derived: sum of 3 quarters · filed 2026-03-26 | $7.94M 10-K · filed 2026-03-26 |
| 2024-09-30 | $633.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.71M derived: sum of 2 quarters · filed 2025-08-12 | $5.10M 10-Q · filed 2024-11-13 | $5.10M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | $2.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.47M 10-Q · filed 2025-08-12 | $4.47M derived: sum of 3 quarters · filed 2025-08-12 | $4.31M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-14 | $2.40M derived: sum of 2 quarters · filed 2025-05-14 | $2.24M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$161.00K derived: sum of 2 quarters · filed 2025-03-25 | $6.56M 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$161.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $6.56M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $6.72M 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $4.32M 10-K · filed 2024-03-27 | |||
| 2011-12-31 | $10.00M 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B |